<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Systemic treatment for unresectable malignant pleural mesothelioma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Systemic treatment for unresectable malignant pleural mesothelioma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Systemic treatment for unresectable malignant pleural mesothelioma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne S Tsao, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James R Jett, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rogerio C Lilenbaum, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, less commonly from the peritoneal surface, and extremely rarely from the tunica vaginalis or pericardium. It often has an extremely poor prognosis; the median survival is 4 to 13 months for untreated patients [
         <a href="#rid1">
          1
         </a>
         ] and 6 to 18 months for treated patients, regardless of the therapeutic approach [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p>
         The systemic treatment of unresectable malignant pleural mesothelioma (MPM) will be reviewed here, while the application of chemotherapy as a component of a combined-modality approach that includes definitive surgery is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">
          "Initial management of malignant pleural mesothelioma"
         </a>
         .)
        </p>
        <p>
         Other related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4608.html" rel="external">
          "Pathology of malignant pleural mesothelioma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4625.html" rel="external">
          "Epidemiology of malignant pleural mesothelioma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4626.html" rel="external">
          "Initial management of malignant pleural mesothelioma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">
          "Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1937732754">
         <span class="h1">
          INITIAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presentation and initial evaluation of MPM is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4627.html" rel="external">
          "Presentation, initial evaluation, and prognosis of malignant pleural mesothelioma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1937732919">
         <span class="h1">
          FIRST-LINE TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4223383150">
         <span class="h2">
          Nonepithelioid histology
         </span>
        </p>
        <p class="headingAnchor" id="H4259687384">
         <span class="h3">
          Nivolumab plus ipilimumab (preferred)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         is approved by the US Food and Drug Administration (FDA) for unresectable mesothelioma [
         <a href="#rid5">
          5,6
         </a>
         ], and is our suggested initial option for patients with nonepithelioid tumors  (
         <a class="graphic graphic_algorithm graphicRef130516" href="/z/d/graphic/130516.html" rel="external">
          algorithm 1
         </a>
         ). However, it is also acceptable to use front-line chemotherapy, reserving nivolumab plus ipilimumab as a subsequent-line option. (See
         <a class="local">
          'Pemetrexed plus cisplatin'
         </a>
         below.)
        </p>
        <p>
         In a phase III trial including 605 patients with advanced,
         <strong>
          treatment-naïve
         </strong>
         mesothelioma, patients were assigned to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         (3 mg/kg intravenously once every two weeks) plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (1 mg/kg intravenously once every six weeks) for up to two years, or platinum plus
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         chemotherapy (pemetrexed [500 mg/m
         <sup>
          2
         </sup>
         intravenously] plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         [75 mg/m
         <sup>
          2
         </sup>
         intravenously] or
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         [area under the concentration-time curve 5 mg/mL per min intravenously]) once every three weeks for up to six cycles [
         <a href="#rid7">
          7
         </a>
         ]. At a median follow-up of 30 months, the median overall survival (OS) for those in the nivolumab/ipilimumab group was 18 months, versus 14 months for those assigned to a platinum agent plus pemetrexed (hazard ratio [HR] 0.74, 96.6% CI 0.60-0.91). Two-year OS rates were 41 versus 27 percent, respectively. Subsequently reported three-year OS results were 23 versus 15 percent, respectively [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         In subgroup analysis, improvements compared with chemotherapy were statistically significant among those with nonepithelioid histologies (18 versus 9 months for
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         versus chemotherapy [HR 0.46, 95% CI 0.31-0.68]), but not for epithelioid histology (19 versus 17 months, respectively [HR 0.86, 95% CI 0.69-1.08]). However, the trial was not powered to determine statistically significant differences within subgroups.
        </p>
        <p>
         The presence of programmed cell death ligand 1 (PD-L1) also predicted improvement with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         over chemotherapy (18 versus 13 months, respectively [HR 0.69, 95% CI 0.55-0.87]), but according to the authors of the study, PD-L1 results were descriptive only, precluding firm conclusions. Grade ≥3 treatment-related adverse events occurred in approximately one-third of patients in both groups, but 15 percent discontinued treatment due to toxicity in the immunotherapy group, versus 7 percent in the chemotherapy group.
        </p>
        <p>
         Additionally,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         monotherapy in the salvage setting as well as the combination of
         <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">
          durvalumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         in the front-line setting have shown promising activity in a phase II study of patients with unresectable mesothelioma (any histology) [
         <a href="#rid9">
          9,10
         </a>
         ], but further investigation is necessary.
        </p>
        <p class="headingAnchor" id="H2324310048">
         <span class="h2">
          Epithelioid histology
         </span>
        </p>
        <p class="headingAnchor" id="H1937732994">
         <span class="h3">
          Pemetrexed plus cisplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         for patients with unresectable malignant epithelioid mesothelioma (as for adjuvant or neoadjuvant therapy  (
         <a class="graphic graphic_algorithm graphicRef130516" href="/z/d/graphic/130516.html" rel="external">
          algorithm 1
         </a>
         )), although
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         represents a reasonable alternative, particularly for those who are unlikely to tolerate chemotherapy. (See
         <a class="local">
          'Nivolumab plus ipilimumab (preferred)'
         </a>
         above.)
        </p>
        <p>
         After completion of four to six cycles of a platinum-based doublet, some UpToDate experts treat patients with maintenance
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         until progression (analogous to use in nonsquamous non-small cell lung cancer [NSCLC]), although data regarding maintenance pemetrexed in mesothelioma are preliminary and limited. The possible addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is discussed below. (See
         <a class="local">
          'Addition of bevacizumab'
         </a>
         below.)
        </p>
        <p>
         The combination of
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         and
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , incorporating prophylactic
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         , increased OS compared with single-agent cisplatin in patients with MPM whose disease was either unresectable or who were not otherwise candidates for potentially curative surgery. In the single-blinded EMPHACIS trial, 456 patients were treated with cisplatin (75 mg/m
         <sup>
          2
         </sup>
         ) and randomly assigned to either pemetrexed (500 mg/m
         <sup>
          2
         </sup>
         ) or placebo, given once every three weeks [
         <a href="#rid11">
          11
         </a>
         ]. The median survival was improved for the combination (12.1 versus 9.3 months), as was the time to progression (5.7 versus 3.9 months) and the objective response rate (41 versus 17 percent). The EMPHACIS trial did not have a maintenance pemetrexed arm.
        </p>
        <p>
         Differences in survival were most striking in patients who received supplementation with
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         during therapy [
         <a href="#rid11">
          11
         </a>
         ]. Furthermore, treatment-related toxicity was significantly less, and the mean number of administered cycles of therapy (both single-agent
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         as well as the combination) was significantly greater in supplemented compared with nonsupplemented patients [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         In regards to
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         maintenance, in preliminary data from a randomized trial of 49 patients with unresectable MPM and at least stable disease after four to six cycles of pemetrexed and platinum-based chemotherapy, median progression-free survival (PFS) between those assigned to pemetrexed maintenance versus observation was similar (3.4 versus 3 months) [
         <a href="#rid13">
          13
         </a>
         ]. Median OS was 16.3 months with pemetrexed and 11.8 months with observation, a difference that was not statistically significant. Given that this trial was small and may not have identified a benefit even if it existed, and that the results are preliminary, some UpToDate experts continue to administer maintenance pemetrexed to patients who have not progressed after initial chemotherapy, although others do offer it, or use it only selectively. A separate trial suggested a PFS benefit with maintenance
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ], but given the lack of OS benefit, this is not a recommended approach.
        </p>
        <p>
         There are no recommended standard assays for predictive biomarkers. However, in a multivariate regression analysis of prognostic factors derived from EMPHACIS, factors predictive of longer OS were therapy group, vitamin supplementation group, Karnofsky performance status (90 to 100 versus 70 to 80  (
         <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">
          table 1
         </a>
         )), disease stage, epithelioid subtype, and white blood cell count (≥8200/microL versus lower values) [
         <a href="#rid15">
          15
         </a>
         ]. Additionally, a retrospective study of 60 MPM patients correlated low thymidylate synthase levels with improved time to progression and OS on pemetrexed-based treatment [
         <a href="#rid16">
          16
         </a>
         ]. Prospective trials to evaluate thymidylate synthase as a predictive biomarker for
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         therapy are ongoing.
        </p>
        <p class="headingAnchor" id="H1279610867">
         <span class="h3">
          Additional considerations
         </span>
        </p>
        <p class="headingAnchor" id="H283584673">
         <span class="h4">
          Addition of bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate contributors are divided in regards to their approach, with some not administering
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and others administering it to select patients with a good performance status. Specifically, if bevacizumab is being considered, patients should have no contraindications (eg, poorly controlled hypertension, deep venous thrombosis, proximity to surgery, or viscous perforation). Also, given the poorer prognosis in older adult NSCLC patients with bevacizumab treatment, this agent should be used with caution in patients over the age of 75.
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to the pemetrexed-cisplatin regimen improved both PFS and OS compared with
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         without bevacizumab in a large phase III trial, but other trials evaluating the addition of antiangiogenic agents to chemotherapy have yielded discrepant results. Based on the results of the MAPS study discussed below, cisplatin-pemetrexed-bevacizumab is the accepted standard in France [
         <a href="#rid17">
          17
         </a>
         ]. The National Comprehensive Cancer Network guidelines have included this regimen as an option for standard front-line therapy, although some insurance companies may not cover it until FDA approval is given.
        </p>
        <p>
         In the MAPS trial, 448 patients were randomly assigned to pemetrexed-cisplatin plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or to pemetrexed-cisplatin alone. The trial was limited to patients with MPM, and only patients who were not eligible for radical surgery were included.
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         (75 mg/m
         <sup>
          2
         </sup>
         ) and
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         (500 mg/m
         <sup>
          2
         </sup>
         ) were given on day 1 of each of six 21-day cycles. Bevacizumab was given at a dose of 15 mg/kg on day 1, and was continued as maintenance every three weeks following completion of six cycles of chemotherapy. No crossover was allowed.
        </p>
        <p>
         Results were as follows [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With a median follow-up of 39 months, PFS was increased with the
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         combination compared with cisplatin-pemetrexed alone (median, 9.2 versus 7.3 months; HR 0.61, 95% CI 0.50-0.75).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         OS was increased with the combination as well (median, 18.8 versus 16.1 months; HR 0.77, 95% CI 0.62-0.95).
        </p>
        <p>
        </p>
        <p>
         These improvements are in contrast to a prior phase II trial, in which
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         maintenance did not demonstrate the expected improvement in PFS relative to historical controls, although the chemotherapy backbone in this study was
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         and
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         [
         <a href="#rid18">
          18
         </a>
         ]. In a separate randomized trial, patients receiving cisplatin-pemetrexed with cediranib had a median PFS of 7.2 versus 5.6 months among those receiving the same chemotherapy with placebo (HR 0.71, 80% CI 0.59-0.95) [
         <a href="#rid19">
          19
         </a>
         ]. OS was similar between the two groups, but toxicities among those receiving cediranib were greater (including more grade 3 and 4 diarrhea, dehydration, and weight loss).
        </p>
        <p class="headingAnchor" id="H2734965101">
         <span class="h4">
          Role for tumor-treating fields?
         </span>
         <span class="headingEndMark">
          —
         </span>
         The FDA has approved a tumor-treating fields (TTF) delivery system for use in combination with
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         plus platinum-based chemotherapy for the first-line treatment of patients with unresectable, locally advanced, or metastatic MPM [
         <a href="#rid20">
          20
         </a>
         ]. However, given the availability only of limited observational data, as well as associated toxicities, we do not routinely use this therapy.
        </p>
        <p>
         The system uses electric fields at specific frequencies to disrupt solid tumor cancer cell division. Its approval was based on results of a phase II trial in which 80 patients with unresectable, treatment-naïve MPM were treated with continuous 150 kHz TTF (≥18 hours/day) plus standard dosing of
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         with either
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ]. The median OS (18 months) was longer than historic control (12 months). Median PFS was 7.6 versus 5.7 months in the historic control. TTF-related dermatitis was reported in 46 percent, and 5 percent had grade 3 dermatitis. Grade 3 to 4 adverse events were noted in 46 percent.
        </p>
        <p class="headingAnchor" id="H1383601610">
         <span class="h2">
          Alternatives
         </span>
        </p>
        <p class="headingAnchor" id="H2091587114">
         <span class="h3">
          Pemetrexed, platinum, and pembrolizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          Pemetrexed
         </a>
         , platinum, and
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is an alternative strategy to the options suggested above and has shown a modest survival benefit over chemotherapy alone in a randomized trial, but with higher toxicities. Benefit was more apparent in patients with nonepithelioid histologies, but this option has not been compared against
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . As such, it remains less preferred than the options discussed above.
        </p>
        <p>
         In an open-label, randomized trial including 440 patients with untreated advanced pleural mesothelioma, the addition of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (up to two years) to six cycles of platinum and pemetrexed-based chemotherapy improved median OS (17.3 versus 16.1 months; HR 0.79, 95% CI 0.64-0.98) [
         <a href="#rid22">
          22
         </a>
         ]. Three year OS rates were 25 versus 17 percent, respectively. Median PFS was comparable (7.13 months among those receiving pembrolizumab and chemotherapy and 7.16 months among those receiving chemotherapy alone). Objective response rate was 62 versus 38 percent, respectively.
        </p>
        <p>
         In an exploratory analysis, patients with nonepithelioid histologies appeared to benefit more from the addition of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (median OS 12.3 versus 9.2 months; HR 0.57, 95% CI 0.36-0.89) than those with epithelioid histologies (median OS 19.8 versus 18.2 months; HR 0.89, 95% CI 0.7-1.13).
        </p>
        <p>
         Grade 3 or 4 related events were reported in 27 percent in the pembrolizumab-chemotherapy group and 15 percent in the chemotherapy group. The most frequently occurring adverse events in both groups were fatigue and nausea. Diarrhea, skin effects, and myelosuppression were more common in the pembrolizumab-chemotherapy group, with greater need for blood transfusions (25 versus 16 percent) and more episodes of febrile neutropenia (5 versus 1 percent).
        </p>
        <p class="headingAnchor" id="H1937733683">
         <span class="h3">
          Pemetrexed plus carboplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          Carboplatin
         </a>
         has been substituted for
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         in conjunction with
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         in an effort to decrease toxicity [
         <a href="#rid23">
          23-25
         </a>
         ]. This approach is an appropriate alternative for patients who may not tolerate cisplatin, for example, those with baseline hearing deficits, in whom the potential for ototoxicity with cisplatin is less acceptable. Carboplatin is, however, associated with greater hematologic toxicity than cisplatin.
        </p>
        <p>
         In the larger of two nonrandomized phase II studies, 102 patients were treated every 21 days with
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         (area under the curve 5) plus
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         (500 mg/m
         <sup>
          2
         </sup>
         ), with
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         supplementation [
         <a href="#rid23">
          23
         </a>
         ]. Objective responses were observed in 19 percent, with a median time to progression of 6.5 months and a median survival of 12.7 months. A secondary analysis of two of these trials based upon patient age found that the carboplatin-plus-pemetrexed regimen was well tolerated and had a similar level of activity in those ≥70 years of age compared with those who were younger [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         These results are similar to those with the cisplatin-based combination, and
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         may be an alternative regimen if
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         toxicity is a particular concern. There are no data from large studies on the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to the pemetrexed-carboplatin regimen.
        </p>
        <p class="headingAnchor" id="H863409903">
         <span class="h3">
          Other options
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gemcitabine
         </strong>
         <strong>
          plus platinum compounds
         </strong>
         –
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          Gemcitabine
         </a>
         has been combined with platinum compounds, including
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         [
         <a href="#rid27">
          27-31
         </a>
         ],
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         [
         <a href="#rid32">
          32
         </a>
         ], and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ]. Response rates for these combinations have ranged from 15 to 48 percent, with acceptable levels of toxicity. However, gemcitabine has not been compared with
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         , and it is generally accepted that mesothelioma patients should receive pemetrexed-based therapy in the first-line setting. (See
         <a class="local">
          'Pemetrexed plus cisplatin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The gemcitabine-plus-cisplatin regimen was evaluated in a multicenter phase II trial, in which 106 previously untreated patients were treated with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and randomly assigned to receive either
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or placebo [
         <a href="#rid31">
          31
         </a>
         ]. The median survival was approximately 15 months on both treatment arms, consistent with the results seen with cisplatin plus
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. No OS benefit was observed with the addition of bevacizumab in this regimen; however, a potential benefit may have been obscured by the use of pemetrexed as second-line therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         <strong>
          cisplatin
         </strong>
         <strong>
          -based combinations
         </strong>
         –
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         has also been combined with a number of older chemotherapy agents in phase II studies. These include anthracyclines (
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">
          epirubicin
         </a>
         ) [
         <a href="#rid35">
          35-38
         </a>
         ]; the combination of
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         , plus
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         [
         <a href="#rid35">
          35-37
         </a>
         ]; and the combination of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         plus
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The results from these studies do not suggest any advantage compared with combinations of
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         plus either
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         or
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , and in fact may be somewhat inferior [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3397146784">
         <span class="h1">
          RESPONSE ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unresectable malignant mesothelioma, response assessment typically includes computed tomography (CT) scans of the chest, abdomen, and pelvis, obtained for any change in clinical status, or routinely during every two to three cycles of treatment. Some UpToDate contributors prefer positron emission tomography combined with CT scanning (PET/CT) rather than CT alone. PET/CT can detect a decrease in metabolic activity in the tumor and may be a better predictor of time to progression rather than objective response as determined by CT alone [
         <a href="#rid42">
          42
         </a>
         ]. However, the PET/CT endpoint has not been validated in phase III trials.
        </p>
        <p>
         Measurement of serum levels of soluble mesothelin-related peptide has been suggested as a way of detecting recurrence of disease after surgical resection, but is not used in routine clinical care. It is not a US Food and Drug Administration-approved assay and does not reliably correlate with response to systemic treatment [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          SUBSEQUENT-LINE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to change therapy is often based on radiographic findings of progression (ie, new or worsening disease) and/or clinical deterioration with more symptoms of pain, shortness of breath, or weight loss. Patients who have significant side effects to treatment may also require a change in therapy.
        </p>
        <p>
         There are no US Food and Drug Administration (FDA)-approved therapies for salvage treatment of mesothelioma. Our approach depends on the initial therapy administered.
        </p>
        <p class="headingAnchor" id="H353696883">
         <span class="h2">
          For those initially treated with immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients treated initially with immunotherapy, second-line treatment consists of chemotherapy  (
         <a class="graphic graphic_algorithm graphicRef130516" href="/z/d/graphic/130516.html" rel="external">
          algorithm 1
         </a>
         ). For those who are appropriate candidates for combination chemotherapy,
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         would be the preferred option, with pemetrexed plus
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         as a reasonable alternative. (See
         <a class="local">
          'Pemetrexed plus cisplatin'
         </a>
         above and
         <a class="local">
          'Pemetrexed plus carboplatin'
         </a>
         above.)
        </p>
        <p>
         However, for those who are unlikely to tolerate combination chemotherapy, single-agent chemotherapy (eg,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         , or
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         ) may be offered.
        </p>
        <p class="headingAnchor" id="H2984724957">
         <span class="h2">
          For those initially treated with chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to such patients depends on whether or not progression occurred after a prolonged period off treatment  (
         <a class="graphic graphic_algorithm graphicRef130516" href="/z/d/graphic/130516.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3037921425">
         <span class="h3">
          Progression &gt;6 months after completion of platinum-based therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If patients developed disease progression in the setting of a prolonged treatment break from a platinum-pemetrexed-based regimen (&gt;6 months), they can be rechallenged with the platinum-pemetrexed-based regimen before attempting further lines of single-agent therapy. (See
         <a class="local">
          'First-line treatment'
         </a>
         above.)
        </p>
        <p>
         If a patient developed disease progression in the setting of a
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         maintenance therapy (but &gt;6 months from platinum-pemetrexed), a reasonable option would be
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , or participation in a clinical trial. (See
         <a class="local">
          'Other options'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1119025938">
         <span class="h3">
          Progression on or within 6 months of platinum-based therapy
         </span>
        </p>
        <p class="headingAnchor" id="H2657401124">
         <span class="h4">
          Choosing between immunotherapy and chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several phase II studies have found that a number of agents lead to improved response rates in the second-line setting for mesothelioma, and, in general, either immunotherapy or single-agent chemotherapy is appropriate.
        </p>
        <p>
         Although the most extensive data in the second-line setting are for
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         (either alone or in combination with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ) [
         <a href="#rid44">
          44-49
         </a>
         ], many patients will have received pemetrexed in the front-line setting. If progression occurred on treatment or within six months of cessation of pemetrexed, we select an agent other than pemetrexed, with some UpToDate experts favoring immunotherapy over chemotherapy in this setting, particularly given that rapid deterioration is common among patients who have experienced progression after initial treatment for mesothelioma, and that immunotherapy may represent a more tolerable option for some.
        </p>
        <p>
         However, other UpToDate experts feel that single-agent chemotherapy represents another appropriate option, including single-agent
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid50">
          50-52
         </a>
         ], vinca alkaloids [
         <a href="#rid52">
          52-54
         </a>
         ], and anthracyclines [
         <a href="#rid55">
          55-57
         </a>
         ]. (See
         <a class="local">
          'Immunotherapy'
         </a>
         below and
         <a class="local">
          'Single-agent chemotherapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3634660521">
         <span class="h4">
          Immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunotherapy using checkpoint inhibitors offers a promising option for disease control [
         <a href="#rid58">
          58,59
         </a>
         ]. The anti-programmed cell death protein 1 (PD-1) antibodies
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         as single agents, or nivolumab with the cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         , are appropriate options for MPM that have shown promising activity, and nivolumab plus ipilimumab has been approved by the FDA for unresectable mesothelioma [
         <a href="#rid5">
          5,6
         </a>
         ]. Toxicities of these agents are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Single-agent immunotherapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pembrolizumab
         </strong>
         – In preliminary results of a phase III trial of 144 patients with advanced pretreated mesothelioma,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         improved objective response rate relative to
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         or
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         (22 versus 6 percent), but both progression-free survival (PFS; 2.5 and 3.4 months) and overall survival (OS; 10.7 and 11.7 months) for pembrolizumab versus chemotherapy, respectively, were similar [
         <a href="#rid60">
          60
         </a>
         ]. In a separate study, treatment of 25 mesothelioma patients (88 percent with previous systemic therapy) with pembrolizumab resulted in five partial responses and 13 patients with stable disease, for an overall disease control rate of 72 percent [
         <a href="#rid59">
          59
         </a>
         ]. All responding patients remained on therapy at the time of analysis. Additional clinical studies with pembrolizumab are being initiated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nivolumab
         </strong>
         – In a double-blind, placebo-controlled phase III trial, among 332 patients with platinum-refractory mesothelioma (95 percent with pleural mesothelioma), those assigned to
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         experienced improvements in both PFS (3.0 versus 1.8 months; hazard ratio [HR] 0.67, 95% CI 0.53-0.85) and OS (10.2 versus 6.9 months; HR 0.69, 95% CI 0.52-0.91) [
         <a href="#rid61">
          61
         </a>
         ]. The most frequently reported grade ≥3 treatment-related adverse events were diarrhea (3 percent in the nivolumab group and 2 percent in the placebo group) and infusion-related reaction (3 versus 0 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Preliminary results of a separate phase II trial including patients with previously treated and relapsed mesothelioma reported objective response rate and disease control rate of 18 and 40 percent, respectively, with single-agent
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nivolumab
         </strong>
         <strong>
          and
         </strong>
         <strong>
          ipilimumab
         </strong>
         – This same trial included a nivolumab-and-ipilimumab arm, in whom objective response rate and disease control rate were 24 and 52 percent, respectively, in an intention-to-treat population [
         <a href="#rid58">
          58
         </a>
         ]. In a separate, single-arm phase II trial of patients with previously treated and relapsed mesothelioma, the response rate was 29 percent with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         and
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         , and 38 percent had stable disease [
         <a href="#rid58">
          58,62
         </a>
         ]. Results for nivolumab plus ipilimumab among treatment-naïve patients are discussed above. (See
         <a class="local">
          'Nivolumab plus ipilimumab (preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other immunotherapies
         </strong>
         – Other immunotherapies, such as the CTLA-4 inhibitor
         <a class="drug drug_general" data-topicid="139983" href="/z/d/drug information/139983.html" rel="external">
          tremelimumab
         </a>
         , were studied in a randomized phase II trial of 571 patients (DETERMINE) but unfortunately showed no survival benefit beyond placebo (7.7 versus 7.3 months, respectively; HR 0.92, 95% CI 0·76-1·12) [
         <a href="#rid63">
          63
         </a>
         ]. Tremelimumab has also been evaluated in combination with the anti-programmed cell death ligand 1 (PD-L1) antibody
         <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">
          durvalumab
         </a>
         in a phase II study, with some suggestion of activity, though randomized data are required [
         <a href="#rid64">
          64
         </a>
         ]. Older immunotherapeutic approaches using interferons or interleukin-2, either alone or in combination with chemotherapy, did not offer substantive advantage [
         <a href="#rid65">
          65-68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3663638207">
         <span class="h4">
          Single-agent chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although single-agent chemotherapy has not been shown to prolong survival in previously untreated patients [
         <a href="#rid34">
          34
         </a>
         ], an analysis of the phase III EMPHACIS trial identified second-line (poststudy) chemotherapy as a significant predictor of extended survival [
         <a href="#rid11">
          11,49
         </a>
         ]. First-line therapy and further results of this study are discussed elsewhere. (See
         <a class="local">
          'Pemetrexed plus cisplatin'
         </a>
         above.)
        </p>
        <p>
         Second-line chemotherapy options include single-agent
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid50">
          50-52
         </a>
         ], vinca alkaloids [
         <a href="#rid52">
          52-54
         </a>
         ], and anthracyclines [
         <a href="#rid55">
          55-57
         </a>
         ]. Given likely comparable efficacy among second-line agents, a choice among them must take into account the relative side effect profiles. Gemcitabine causes myalgias and flu-like symptoms, while
         <a class="drug drug_general" data-topicid="10046" href="/z/d/drug information/10046.html" rel="external">
          vinorelbine
         </a>
         is more frequently associated with neuropathy and requires a central line because of the risk of extravasation. Anthracyclines are associated with cardiotoxicity, which limits the acceptable duration of treatment. All can cause myelosuppression. Other agents with single-agent activity include
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid69">
          69
         </a>
         ], edatrexate [
         <a href="#rid70">
          70
         </a>
         ], and
         <a class="drug drug_general" data-topicid="10087" href="/z/d/drug information/10087.html" rel="external">
          raltitrexed
         </a>
         [
         <a href="#rid71">
          71
         </a>
         ], and these may be options for later-line therapy.
        </p>
        <p>
         Although a small, randomized trial (RAMES) showed a survival benefit with the addition of the angiogenesis inhibitor
         <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">
          ramucirumab
         </a>
         to
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (13.8 versus 7.5 months, respectively; HR 0.71, 90% CI 0.53-0.95) [
         <a href="#rid72">
          72
         </a>
         ], further data are needed prior to routine use of this combination outside of a clinical trial.
        </p>
        <p>
         For those who for whatever reason were not exposed to
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         (or had a prolonged treatment-free interval), it remains an appropriate choice. In a study of 243 previously treated patients randomly assigned to pemetrexed or best supportive care, pemetrexed significantly increased the median PFS, time to progression, and time to treatment failure (3.6 versus 1.5, 3.7 versus 1.5, and 3.6 versus 1.5 months, respectively) [
         <a href="#rid48">
          48
         </a>
         ]. However, pemetrexed did not improve median survival (8.4 versus 9.7 months with best supportive care). An OS benefit may have been obscured, since 52 percent of those assigned to best supportive care received systemic chemotherapy once disease progression was evident.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          INVESTIGATIONAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A range of other approaches have been or are being studied in an effort to improve upon the systemic therapy for MPM. None of these has an established role in the treatment of mesothelioma and is not indicated outside the context of a formal clinical trial.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although addition of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         (a vascular endothelial growth factor [VEGFR], platelet-derived growth factor receptor [PDGFR], and fibroblast growth factor receptor [FGFR] tyrosine kinase inhibitor) to chemotherapy showed progression-free survival (PFS) benefit in a phase II trial [
         <a href="#rid73">
          73
         </a>
         ], there was no observed benefit in the phase III trial (6.8 versus 7 months among those receiving chemotherapy with or without nintedanib) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9491" href="/z/d/drug information/9491.html" rel="external">
          Vorinostat
         </a>
         , an oral histone deacetylase inhibitor, showed some evidence of activity in an initial phase I study [
         <a href="#rid75">
          75
         </a>
         ]. However, more extensive evaluation did not confirm a clinically meaningful benefit from this approach. In a phase III trial, 661 previously treated patients were randomly assigned to either vorinostat or placebo [
         <a href="#rid76">
          76
         </a>
         ]. PFS was prolonged with vorinostat (median, 6.3 versus 6.1 weeks; hazard ratio [HR] 0.75, 95% CI 0.63-0.88). However, this increase was not clinically significant. Also, the difference in overall survival was not significant (median, 30.7 versus 27.1 weeks; HR 0.98, 95% CI 0.83-1.17).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agents targeting mesothelin, such as MORAb-009, SS1P, BAY 9409343, and CRS-207, have showed preliminary efficacy against mesothelioma in clinical trials. Several randomized trials are ongoing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other experimental agents that have been studied include angiogenesis inhibitors (
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         [
         <a href="#rid77">
          77
         </a>
         ]),
         <a class="drug drug_general" data-topicid="128469" href="/z/d/drug information/128469.html" rel="external">
          lurbinectedin
         </a>
         [
         <a href="#rid78">
          78
         </a>
         ], and tyrosine kinase inhibitors (
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ],
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ],
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid80">
          80-82
         </a>
         ], vatalanib [
         <a href="#rid83">
          83
         </a>
         ], and cediranib [
         <a href="#rid84">
          84
         </a>
         ]).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2202508598">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">
          "Society guideline links: Diagnosis and management of lung cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/129230.html" rel="external">
          "Society guideline links: Pleural mesothelioma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32892193">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83443.html" rel="external">
          "Patient education: Pleural mesothelioma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment algorithm
         </strong>
         – Our treatment approach is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef130516" href="/z/d/graphic/130516.html" rel="external">
          algorithm 1
         </a>
         ) and in the points below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with advanced malignant pleural mesotheliomas (MPM) who are not candidates for surgery, our approach to initial therapy depends on histology:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those with
         <strong>
          nonepithelioid
         </strong>
         histologies, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         rather than chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ), although the opposite sequence is also acceptable.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For those with
         <strong>
          epithelioid
         </strong>
         histologies, we suggest combination chemotherapy using a
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         and a platinum agent, with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), although nivolumab plus ipilimumab is a reasonable alternative, particularly for those who are unlikely to tolerate chemotherapy. (See
         <a class="local">
          'First-line treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When using chemotherapy with
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         , we also include prophylactic
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9302" href="/z/d/drug information/9302.html" rel="external">
          vitamin B12
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to platinum and
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         has been shown to increase overall survival. At this time, regulatory approval is pending for bevacizumab with
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         and pemetrexed, and UpToDate contributors are divided in regards to whether or not they incorporate it. If bevacizumab is considered, patients should be typically &lt;75 years of age, with a good performance status, and without contraindications. (See
         <a class="local">
          'Addition of bevacizumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Some UpToDate contributors use maintenance
         <a class="drug drug_general" data-topicid="10098" href="/z/d/drug information/10098.html" rel="external">
          pemetrexed
         </a>
         after four to six cycles of the platinum-pemetrexed doublet, rather than discontinuation of treatment, extrapolating from data in the non-small cell lung cancer setting. However, other UpToDate contributors do not use maintenance pemetrexed. (See
         <a class="local">
          'Pemetrexed plus cisplatin'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/90312.html" rel="external">
          "Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Maintenance therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We suggest against the routine addition of tumor-treated fields to chemotherapy for advanced MPM, given associated toxicities and the availability of only limited, nonrandomized data (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternatively, however, it is acceptable to use it in select patients who accept the risks of toxicities and limitations in available data. (See
         <a class="local">
          'Role for tumor-treating fields?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent-line treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those who experience progression on initial treatment with immunotherapy, next-line treatment is with chemotherapy, with a choice between single and combination therapy dependent on the patient's performance status and preferences. (See
         <a class="local">
          'For those initially treated with immunotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients initially treated with chemotherapy who progress at least six months after completion, we suggest rechallenge with the initial chemotherapy regimen (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Progression &gt;6 months after completion of platinum-based therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients initially treated with chemotherapy who progress on or within six months of their initial regimen, we suggest either immunotherapy or a single-agent chemotherapy agent to which they have not yet been exposed, rather than further treatment with combination chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1695497011">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate acknowledges Dr. Vogelzang's past work as an author for this topic.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107:332S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019; 69:402.
          </a>
         </li>
         <li class="breakAll">
          Nivolumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s089lbl.pdf (Accessed on October 05, 2020).
         </li>
         <li class="breakAll">
          Ipilimumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s115lbl.pdf (Accessed on October 05, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022; 33:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol 2020; 21:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yap TA, Nakagawa K, Fujimoto N, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 2021; 9:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelzang NJ, Emri S, Boyer MJ, et al. Effect of folic acid and vitamin B12 supplmentation on risk-benefit ratio from phase III study of pemetrexed and cisplatin versus cisplatin in malignan pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 2003; 22:657a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dudek AZ, Wang XF, Gu L, et al. Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). J Clin Oncol 2019; 37S: ASCO #8517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Gooijer CJ, van der Noort V, Stigt JA, et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med 2021; 9:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symanowski JT, Rusthoven J, Nguyen B, et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 2003; 22:647a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013; 109:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsao AS, Miao J, Wistuba II, et al. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol 2019; 37:2537.
          </a>
         </li>
         <li class="breakAll">
          NovoTTF-100L System. United States Prescribing Information. US National Library of Medicine. https://www.fda.gov/medical-devices/recently-approved-devices/novottftm-100l-system-h180002 (Accessed on June 19, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019; 20:1702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 2023; 402:2295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceresoli GL, Castagneto B, Zucali PA, et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008; 99:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jänne PA, Simon GR, Langer CJ, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 2008; 26:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovac V, Zwitter M, Rajer M, et al. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 2012; 23:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97:2791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schutte W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003; 4:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogelzang NJ. Chemotherapy for malignant pleural mesothelioma. Lancet 2008; 371:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991; 67:2984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henss H, Fiebig HH, Schildge J, et al. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988; 11:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berghmans T, Lafitte JJ, Paesmans M, et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005; 50:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996; 109:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006; 24:4587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28:3316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008; 3:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jänne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006; 1:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26:1698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Meerbeeck JP, Baas P, Debruyne C, et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999; 85:2577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kindler HL, Millard F, Herndon JE 2nd, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001; 31:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toyokawa G, Takenoyama M, Hirai F, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014; 19:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18:3912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007; 25:4751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee. Tumori 1991; 77:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 2002; 20:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. J Clin Oncol 2017; 35S: ASCO #LBA8507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017; 18:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popat S, Curioni-Fontecedro A, Polydoropoulou V, et al. A multicentre randomized phase III trial comparing pembrolizumab (P) versus single-agent chemotherapy (CT) for advanced pretreated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2019; 30S: ESMO #LBA91_PR.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021; 22:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019; 7:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 2017; 18:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med 2018; 6:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001; 92:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bretti S, Berruti A, Dogliotti L, et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998; 84:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013; 14:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kindler HL, Belani CP, Herndon JE 2nd, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 1999; 86:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baas P, Ardizzoni A, Grossi F, et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003; 39:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021; 22:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol 2017; 35:3591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2019; 7:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015; 16:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 2013; 14:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metaxas Y, Früh M, Eboulet EI, et al. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). Ann Oncol 2020; 31:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nowak AK, Millward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2008; 26S: ASCO #8063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007; 59:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma (abstract 912). Proc Am Soc Clin Oncol 2003; 22:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang XF, et al, Janne PA, Krug LM. Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol 2007; 25S: ASCO #7707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Schil PE, Baas P, Gaafar R, et al. Phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy for cT3N1M0 or less malignant pleural mesothelioma (EORTC 08031). J Clin Oncol 2008; 27S: ASCO #7509.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4609 Version 58.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8622005" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chemotherapy in malignant pleural mesothelioma. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8462328" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Natural history and epidemiology of malignant mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7781415" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Current approach to malignant mesothelioma of the pleura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31283845" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31283845" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31283845" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33485464" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35124183" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888453" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33836153" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12860938" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of folic acid and vitamin B12 supplmentation on risk-benefit ratio from phase III study of pemetrexed and cisplatin versus cisplatin in malignan pleural mesothelioma (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33515500" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20177021" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719230" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23860535" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31386610" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31386610" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31628016" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37931632" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16549838" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156144" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18594322" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18542071" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12189542" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15923792" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18349397" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22027538" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22665541" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12767092" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14609447" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486725" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Chemotherapy for malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8336195" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2044044" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3045724" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16005104" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8625674" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9602260" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486741" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17008700" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20498407" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12697881" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561178" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18594323" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17409909" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18375898" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824080" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10375105" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11165412" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24158772" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099320" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17947722" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Phase II study of vinflunine in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6627213" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2017799" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12197225" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28291584" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A multicentre randomized phase III trial comparing pembrolizumab (P) versus single-agent chemotherapy (CT) for advanced pretreated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34656227" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660511" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28729154" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29773326" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505411" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468296" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9862516" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24035405" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1616870" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10570422" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12565988" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34499874" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28892431" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31103412" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15897550" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800891" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23583604" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32085891" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15951053" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636799" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma (abstract 912)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy for cT3N1M0 or less malignant pleural mesothelioma (EORTC 08031)
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
